CAP-1002

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
CAP-1002
Accession Number
DB15744
Description

Cardiosphere-derived cells (CDCs) are derived from human neonatal heart tissue with a distinct antigenic profile (CD105+, CD45-, and CD90low). They exert their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used for the purpose of cell-cell communication. CDCs target multiple cytokine pathways associated with poor outcomes (e.g. TNFa, IFN-y, IL-1B, and IL-15). The anti-inflammatory effects of CDC work through polarizing macrophages and restoring tissue function.

Type
Biotech
Groups
Investigational
Biologic Classification
Cell transplant therapies
Other cell transplant therapies
Synonyms
Not Available
External IDs
  • CAP-1002

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

Cardiosphere-derived cell exosomes can reduce cardiac scar size, improve myocardial function, and attenuate damaging remodeling that occurs from infections. CAP-1002 was formulated as an intravenous infusion of cardiosphere-derived cells and is currently being investigated as a treatment for critically ill COVID-19 patients.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
ZM7OCV7H6H
CAS number
Not Available

References

General References
  1. Chakravarty T, Makkar RR, Ascheim DD, Traverse JH, Schatz R, DeMaria A, Francis GS, Povsic TJ, Smith RR, Lima JA, Pogoda JM, Marban L, Henry TD: ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: Rationale and Design. Cell Transplant. 2017 Feb 16;26(2):205-214. doi: 10.3727/096368916X692933. Epub 2016 Aug 18. [PubMed:27543900]
  2. Taylor M, Jefferies J, Byrne B, Lima J, Ambale-Venkatesh B, Ostovaneh MR, Makkar R, Goldstein B, Smith RR, Fudge J, Malliaras K, Fedor B, Rudy J, Pogoda JM, Marban L, Ascheim DD, Marban E, Victor RG: Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial. Neurology. 2019 Feb 19;92(8):e866-e878. doi: 10.1212/WNL.0000000000006950. Epub 2019 Jan 23. [PubMed:30674601]
  3. Singh S, Chakravarty T, Chen P, Akhmerov A, Falk J, Friedman O, Zaman T, Ebinger JE, Gheorghiu M, Marban L, Marban E, Makkar RR: Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series. Basic Res Cardiol. 2020 May 12;115(4):36. doi: 10.1007/s00395-020-0795-1. [PubMed:32399655]
  4. Kapelios CJ, Nanas JN, Malliaras K: Allogeneic cardiosphere-derived cells for myocardial regeneration: current progress and recent results. Future Cardiol. 2016 Jan;12(1):87-100. doi: 10.2217/fca.15.72. Epub 2015 Dec 21. [PubMed:26696563]
  5. Saha P, Sharma S, Korutla L, Datla SR, Shoja-Taheri F, Mishra R, Bigham GE, Sarkar M, Morales D, Bittle G, Gunasekaran M, Ambastha C, Arfat MY, Li D, Habertheuer A, Hu R, Platt MO, Yang P, Davis ME, Vallabhajosyula P, Kaushal S: Circulating exosomes derived from transplanted progenitor cells aid the functional recovery of ischemic myocardium. Sci Transl Med. 2019 May 22;11(493). pii: 11/493/eaau1168. doi: 10.1126/scitranslmed.aau1168. [PubMed:31118291]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentGenetic Diseases, Inborn / Genetic Diseases, X-Linked / Muscular Diseases / Muscular Disorders, Atrophic / Muscular Dystrophy / Muscular Dystrophy, Duchenne / Nervous System Diseases / Neuromuscular Diseases1
2Enrolling by InvitationTreatmentDuchenne's Muscular Dystrophy (DMD)1
2RecruitingTreatmentCongestive Heart Failure (CHF) / Heart Failure, Diastolic1
1RecruitingTreatmentPulmonary Arterial Hypertension (PAH)1
1Unknown StatusTreatmentDilated Cardiomyopathy (DCM) / Heart Failure / Ischaemic Cardiomyopathy / Nonischemic Cardiomyopathy1
1, 2CompletedTreatmentCardiomyopathy / Duchenne's Muscular Dystrophy (DMD)1
1, 2TerminatedTreatmentMyocardial Infarction1
Not AvailableAvailableNot AvailableNovel Coronavirus Infectious Disease (COVID-19)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on August 11, 2020 15:15 / Updated on August 13, 2020 01:02

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates